- Home
- NCL vs CASI Comparison
NCL vs CASI Comparison
Compare NCL & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- CASI
- Stock Information
- Founded
- NCL 2013
- CASI 1991
- Country
- NCL United States
- CASI China
- Employees
- NCL N/A
- CASI N/A
- Industry
- NCL
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- CASI Health Care
- Exchange
- NCL Nasdaq
- CASI Nasdaq
- Market Cap
- NCL 21.7M
- CASI 20.5M
- IPO Year
- NCL 2023
- CASI 1996
- Fundamental
- Price
- NCL $0.16
- CASI $1.12
- Analyst Decision
- NCL
- CASI Strong Buy
- Analyst Count
- NCL 0
- CASI 1
- Target Price
- NCL N/A
- CASI $4.00
- AVG Volume (30 Days)
- NCL 17.1M
- CASI 302.8K
- Earning Date
- NCL 08-13-2025
- CASI 08-15-2025
- Dividend Yield
- NCL N/A
- CASI N/A
- EPS Growth
- NCL N/A
- CASI N/A
- EPS
- NCL N/A
- CASI N/A
- Revenue
- NCL $15,576,857.00
- CASI $31,368,000.00
- Revenue This Year
- NCL N/A
- CASI N/A
- Revenue Next Year
- NCL N/A
- CASI N/A
- P/E Ratio
- NCL N/A
- CASI N/A
- Revenue Growth
- NCL 47.13
- CASI 8.39
- 52 Week Low
- NCL $0.15
- CASI $1.09
- 52 Week High
- NCL $1.52
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- NCL 36.24
- CASI 29.29
- Support Level
- NCL $0.16
- CASI $1.22
- Resistance Level
- NCL $0.19
- CASI $1.42
- Average True Range (ATR)
- NCL 0.03
- CASI 0.28
- MACD
- NCL -0.03
- CASI -0.04
- Stochastic Oscillator
- NCL 6.82
- CASI 5.49
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.